[ad_1]
[속보] “If vaccination starts in March, AstraZeneca will be used”
Eunji Kim, Busan.com Reporter [email protected]
Check-in: 2020-12-14 15:20:43Revision: 2020-12-14 16:03:53Published: 2020-12-14 15:23:25
The image is ‘Corona Vaccine 19’ developed by AstraZeneca. Yunhap news
The government said its goal is to complete contracts for two or more vaccine products for infection by the new coronavirus (Corona 19) before the end of the year.
Jung Eun-kyung, head of the Central Defense Countermeasures Headquarters, said in a regular briefing on the 14th: “Although the speed varies by product, at least two or more are currently in talks on the review of the contract with the goal of completing the contract before the end of the year. “
Then Jung said, “(The representative of the ruling party) said the vaccination of the vaccine in March, and the AstraZeneca vaccine is expected to be introduced in Korea as soon as possible,” he said. “It is expected to be produced in Korea and the fastest in terms of lead time.” .
In relation to the response to the new coronavirus infection (Corona 19) the day before, the representative of the Democratic Party, Lee Nak-yeon, said: “We are trying to start using the treatment before the end of January next year and before March vaccination “.
Representative Lee held a press conference in the National Assembly this afternoon and said, “I will do my best to accelerate the use of treatment and vaccination as much as possible while confirming the effectiveness and safety.”
The head of the headquarters, Eun-kyung Jung, adhered to the position that he had to monitor the clinical approvals and vaccination procedures of other countries. He said: “We have to keep an eye on the US and European permitting processes, and review the verification process of the World Health Organization, and the Ministry of Food and Drug Safety administers the permits and prepares to administer immediately. the vaccine after approval, “he said.
Among the COVID-19 treatments being developed in Korea, antibody treatments are expected to be the first.
“We know that (antibody therapy) is currently looking at the data after the phase 2 clinical trials ended.” Said.
“It is hoped that antibody therapy can prevent the severity that leads to death and progresses to severe if given in the initial mild stage,” he added. “We are continually managing and supporting the development process.”
Kim Eun-ji, Busan.com Reporter [email protected]
